References
- Yap Y G, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. British Medical Journal 2000; 320: 1158–1159
- Buckley N, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 2000; 23: 215–228
- Burda C D. Cardiotoxic effects of Mellaril. American Heart Journal 1970; 80: 147
- Fletcher G F, Kazamias T M. Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias. American Heart Journal 1969; 78: 135–138
- Vozza A, Sartorari L, Speciale F. L'impiego dell'associazione proscillaridina A, tioridazina e glucosio-1-fosfato nella terapia delle cardiopatie senili. Giornale di Gerontologia 1972; 20: 542–550
- Wendkos M H. Cardiac changes related to phenothiazine therapy, with special reference to thioridazine. Journal of the American Geriatrics Society 1967; 15: 20–28
- Buckley N A, Whyte I M, Dawson A H. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. Journal of Toxicology –Clinical Toxicology 1995; 33: 199–204
- Reilly J G, Ayis S A, Ferrier I N, Jones S J, Thomas S H. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–1052
- PHARMAC. New Zealand Pharmaceutical Schedule. http://www.pharmac.govt.nz/download/pschedule0402.pdf. 129, [Cited 27 May 2002.]
- Fenichel R R. Development of drugs that alter ventricular repolarization (22 screens). http://www.fenichel.net/qt%20stuff/qtfrozen.doc, [Cited 20 June 2001.]
- Pillans P I, Mathew T H, Coulter D M. Pharmacovigilance in Australia and New Zealand: towards 2000. Medical Journal of Australia 1999; 170: 245–246
- Ackerman M J, Clapham D E. Ion channels – basic science and clinical disease [published erratum appears in New England Journal of Medicine 1997: 337: 579]. New England Journal of Medicine 1997; 336: 1575–1586
- Tie H, Walker B, Valenzuela S, Breit S, Campbell T. The heart of psychotropic drug therapy. Lancet 2000; 355: 1825
- Jo S H, Youm J B, Lee C O, Earm Y E, Ho W K. Blockade of the HERG human cardiac K (+) channel by the antidepressant drug amitriptyline. British Journal of Pharmacology 2000; 129: 1474–1480
- von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clinical Pharmacology and Therapeutics 1991; 49: 234–240
- Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000; 355: 979–983
- Idle J R. The heart of psychotropic drug therapy. Lancet 2000; 355: 1824–1825
- Idle J R, Smith R L. Pharmacogenetics in the new patterns of healthcare delivery. Pharmacogenetics 1995; 5: 347–350
- Hartigan-Go K, Bateman D N, Nyberg G, Martensson E, Thomas S H. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clinical Pharmacology and Therapeutics 1996; 60: 543–553
- Carrillo J A, Ramos S I, Herraiz A G, Llerena A, Agundez J A, Berecz R. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. Journal of Clinical Psychopharmacology 1999; 19: 494–499
- http://www.fda.gov/cder/ogd/rld/17923s48.PDF
- http://www.medsafe.govt.nz/Profs/PUarticles/thioridazine.htm
- Branford D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. Journal of Intellectual Disability Research 1996; 40: 322–329